Dynavax Technologies Corporation (NASDAQ: DVAX) announced initiation of a large-scale Phase 3 trial designed to demonstrate the lot-to-lot consistency of commercial vaccine and to complete the safety database for HEPLISAV™, the Company's investigational adult hepatitis B vaccine. This study and the ongoing Phase 3 trial in chronic kidney disease patients are directed toward fulfilling licensure requirements in the U.S., Canada and Europe. HEPLISAV has been shown in two pivotal Phase 3 trials to enhance protection more rapidly and with fewer doses than a currently licensed vaccine...![](/proxy.php?image=http%3A%2F%2Ffeedads.g.doubleclick.net%2F%7Ea%2F6eP8kIdPvE4F-XeduzAVpGJVco0%2F0%2Fdi&hash=6cc397b8e0b8f4962c8b3dcf4ac9b5fc)
![](/proxy.php?image=http%3A%2F%2Ffeedads.g.doubleclick.net%2F%7Ea%2F6eP8kIdPvE4F-XeduzAVpGJVco0%2F1%2Fdi&hash=bfc61fab5fe16564f5b27f608415f9d7)
More...
More...